SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares	Mar. 31, 2024 USD ($)	Jun. 30, 2023 USD ($) $ / shares	Mar. 31, 2023 USD ($)	Jun. 30, 2024 USD ($) Customer $ / shares	Jun. 30, 2023 USD ($) Customer $ / shares	Dec. 31, 2023 USD ($)
Revenue Recognition [Abstract]
Revenues	$ 107,191		$ 60,123		$ 189,066	$ 117,037
Income from operations	39,201		(473)		61,022	(1,286)
Net income	$ 32,062	$ 17,806	$ (6,371)	$ (6,789)	$ 49,868	$ (13,160)
Basic earnings per share (in dollars per share) | $ / shares	$ 0.14		$ (0.03)		$ 0.22	$ (0.06)
Diluted earnings per share (in dollars per share) | $ / shares	$ 0.13		$ (0.03)		$ 0.21	$ (0.06)
Accrual adjustments	$ 27,726				$ 27,726		$ 32,919
Two Customers [Member] | Revenues [Member] | Customer Concentration Risk [Member]
Revenue Recognition [Abstract]
Number of customers | Customer					2	2
Percentage of consolidated revenues					71.00%	68.00%
Accrual for U.S. Medicaid Rebates [Member]
Revenue Recognition [Abstract]
Revenues	12,600
Income from operations	12,600
Net income	$ 11,600
Basic earnings per share (in dollars per share) | $ / shares	$ 0.05
Diluted earnings per share (in dollars per share) | $ / shares	$ 0.05
Accrual adjustments	$ 12,600				$ 12,600
Biotest License Agreement [Member]
Revenue Recognition [Abstract]
Amortization period					22 years